Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 11Terminated 3Active not recruiting 3Unknown 2Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1Gynecologic 1

Conditions

Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Docetaxel 33Radiosurgery 23Radiotherapy 21Sunitinib 20pembrolizumab 18Gemcitabine 16Cisplatin 16Androgen Antagonists 15Nivolumab 14enzalutamide 13Goserelin 13Prednisone 12Leuprolide 12Blood Specimen Collection 12Abiraterone Acetate 12bicalutamide 11aldesleukin 11Surveys and Questionnaires 11Cyclophosphamide 11Gonadotropin-Releasing Hormone 10Bevacizumab 10Multiparametric Magnetic Resonance Imaging 9Carboplatin 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Triptorelin Pamoate 8Radiotherapy, Intensity-Modulated 8Filgrastim 8Epirubicin 8Chemotherapy, Adjuvant 8Brachytherapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × fluciclovine F-18 × Genitourinary × Clear all
NCT03762759 2024-05-17

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Emory University

Phase 2 Unknown
140 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03996993 2019-06-25

Defining Recurrent Disease With Axuminâ„¢

Cancer Center of Irvine

Unknown
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡